Tarlatamab Shows Promise in Tackling Previously Treated SCLC
The investigational bispecific T-cell engager tarlatamab showed durable responses in patients with small-cell lung cancer (SCLC), particularly at lower doses, with encouraging survival outcomes. The therapy targeted cancer cells expressing DLL3 and demonstrated clinical activity in pretreated patients. Data from phase 1 and phase 2 trials showed overall response rates, progression-free survival, and overall survival….